Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc. (RLMD) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
rlmd · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Relmada Therapeutics, Inc. (RLMD) measures how much investors pay for each dollar of the company's trailing earnings. RLMD's current PE ratio of N/A is calculated by dividing its stock price of $5.72 by its TTM earnings per share of -$0.68.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2012 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Relmada Therapeutics, Inc.You RLMD | $419M | N/A | — | -$0.68 |
 Adicet Bio, Inc. ACET | $67M | N/A | — | -$16.95 |
 Acrivon Therapeutics, Inc. Common Stock ACRV | $44M | N/A | — | -$2.02 |
 Cibus, Inc. CBUS | $56M | N/A | — | -$0.28 |
 Fortress Biotech, Inc. FBIO | $95M | 14.98x | — | $0.24 |
 Immunic, Inc. IMUX | $119M | N/A | — | -$6.24 |
 Lite Strategy, Inc. LITS | $26M | N/A | — | -$2.39 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.45 | — | |
2024-12-31 FY2024 | — | $-2.65 | — | |
2023-12-31 FY2023 | — | $-3.28 | — | |
2022-12-31 FY2022 | — | $-5.30 | — | |
2021-12-31 FY2021 | — | $-7.16 | — | |
2020-12-31 FY2020 | — | $-3.81 | — | |
2019-12-31 FY2019 | — | $-1.63 | — | |
2019-06-30 FY2019 | — | $-2.74 | — | |
2018-06-30 FY2018 | — | $-2.86 | — | |
2017-06-30 FY2017 | — | $-2.08 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Relmada Therapeutics, Inc. (RLMD) measures how much investors pay for each dollar of the company's trailing earnings. RLMD's current PE ratio of N/A is calculated by dividing its stock price of $5.72 by its TTM earnings per share of -$0.68.
Frequently asked questions
RLMD pe ratio · 6 questionsRLMD's current PE ratio is N/A as of 2026-06-09, based on a stock price of $5.72 and TTM EPS of -$0.68. Data sourced from Financial Modeling Prep via RLMD's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Relmada Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09